Synaptive Medical Secures Strategic Investment to Accelerate Growth and Innovation
MedTech leader emerges from restructuring with renewed momentum and an unwavering focus on transformative surgical care.
Article content
TORONTO — Synaptive Medical, a global medical technology innovator, today announced the successful completion of a strategic restructuring and the closing of a significant new private investment. This milestone marks a pivotal new chapter for the company—one that strengthens its mission to revolutionize neurosurgical care in close collaboration with clinicians worldwide.
Article content
'We remain deeply committed to investing in the people, tools, and technologies that drive progress in surgical planning, neuro-navigation, robotic exoscopy, and advanced MRI,' said Cameron Piron, President and Founder of Synaptive Medical. 'From enhancing surgical precision with our integrated robotic and navigation systems to expanding the diagnostic potential of our MRI platforms, Synaptive is redefining the future of surgery—from imaging to intervention.'
Article content
As part of its transformation, Synaptive is reaffirming its commitment to its comprehensive product portfolio. The company will continue to expand its integrated surgical suite—including Modus X™, Modus Nav™, and Modus Plan™ —alongside its dedicated MRI platform. These advancements are closely aligned with long-standing partnerships at leading hospitals and clinical institutions around the world.
Article content
Throughout the restructuring, Synaptive maintained uninterrupted customer support while continuing to execute on its innovation roadmap. Recent milestones include major software upgrades across its platforms and the launch of new collaborations with internationally recognized medical centers in the United States and Europe.
Article content
The newly secured investment will bring the company to profitability and reflects strong confidence in Synaptive's strategic direction and long-term growth. The company has been wholly acquired by a mission-aligned consortium of MedTech executives, clinicians, and experienced investors who bring deep domain expertise and a shared vision for the future of neurosurgical care.
Article content
'This investment represents a powerful recommitment to Synaptive's mission: to transform brain health in the 21st century for patients and families in need,' said Dr. Joshua Bernstock, neurosurgeon and incoming board member. 'We're proud to join forces with a team that is not only passionate about elevating the standard of care but also fearless in pushing the boundaries of what's possible in diagnostics and surgical innovation.'
Article content
This investment represents the first phase of a broader capital initiative, with additional funding expected in the coming weeks to further support Synaptive's growth strategy and accelerate its innovation pipeline.
Article content
About Synaptive Medical
Article content
Synaptive Medical Inc. is a Toronto-based global medical technology company dedicated to solving complex challenges in surgery, imaging, and data integration to improve patient outcomes. Its integrated suite of solutions—spanning MRI, surgical planning, navigation, and robotic visualization—delivers intelligent, patient-centric technology that enhances clinical decision-making and efficiency across every stage of neurosurgical care.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Media:
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
42 minutes ago
- Globe and Mail
Why Are These 3 High-Yield Dividend King Stocks Near 52-Week Lows While the S&P 500 Just Hit an All-Time High?
The S&P 500 (SNPINDEX: ^GSPC) closed out the first half of the year at an all-time high -- a remarkable recovery considering how beaten down the index was in April. But not all stocks are enjoying the rebound. Dividend-paying stocks PepsiCo (NASDAQ: PEP), Kimberly-Clark (NASDAQ: KMB), and Target (NYSE: TGT) have lost value over the last three years because they aren't consistently growing their earnings and consumer spending is under pressure. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » However, these companies are Dividend Kings -- meaning they have paid and raised their payouts for over 50 consecutive years. Here's why Pepsi, Kimberly-Clark, and Target are excellent choices for folks looking to boost their passive income. Challenges are mounting for consumer-facing companies Investing is more about expectations than past performance. So the market can grow intolerant of companies that undergo multiyear periods of slowing or negative growth. That's certainly been the case for Pepsi, Kimberly-Clark, and Target. PEP Revenue (TTM) data by YCharts As the chart shows, all three companies are experiencing slow or negative sales growth, and their stock prices are falling accordingly. PepsiCo owns a variety of beverage and snack brands -- from flagship Pepsi to Gatorade, Mountain Dew, Tropicana, Frito-Lay snack brands like Lay's, Cheetos, Doritos, and Quaker Oats products. The diverse lineup helps make Pepsi a stable stalwart, but the company is seeing intense backlash from consumers who are drained from years of price increases. Pepsi has made some acquisitions focused on healthier snacks and meal replacements to diversify its product lineup. And the company is revamping marketing and packaging efforts to cater to consumers. Still, Pepsi doesn't expect these efforts to offset near-term headwinds, so its guidance is fairly weak. Kimberly-Clark makes paper-based professional products and has consumer brands such as Kleenex, Cottonelle, Viva, and Scott. It also offers a variety of adult care, baby and child care, and feminine care products. But the company is in a similar boat to Pepsi. Demand is flatlining, pressuring Kimberly-Clark's growth rate and margins. A multiyear strategy to reorganize the company has yet to produce tangible results. Target's issues are even more severe. Despite promotions and exclusive product offerings, the company is struggling to boost in-store foot traffic. Target also mismanaged its inventory and hasn't tapped into e-commerce and delivery options nearly as well as peers like Walmart. Whereas Pepsi and Kimberly-Clark sell everyday-use products, Target's product mix is more discretionary in nature -- which has backfired as consumers look for value. Stable and growing payouts Although all three companies are far from the top of their game, they are all still highly profitable. They aren't turnaround stories in dire straits. The payout ratio and free cash flow (FCF) per share compared to the dividend per share are useful metrics for gauging dividend affordability. The payout ratio is a company's earnings per share divided by the dividend per share -- with 50% to 75% generally considered a healthy range. But stable companies in non-cyclical sectors can be on the higher end of that range. As you can see in the following chart, Pepsi, Kimberly-Clark, and Target all have good payout ratios. PEP Payout Ratio data by YCharts Pepsi is earning roughly the same FCF as its dividend, but Kimberly-Clark and Target are generating boatloads more FCF than dividends -- illustrating dividend affordability. Heavily discounted valuations All three companies have seen their valuations fall considerably since they have continued to generate strong earnings, but their stock prices are down. PEP PE Ratio (10y Median) data by YCharts To be fair, when a company is producing below its historical growth rate and not living up to investor expectations, it arguably deserves to trade at a discount. However, all three companies are now down considerably from their average valuations. Pepsi's price-to-earnings (P/E) ratio is now under 20 even though it has historically been a premium-priced stock relative to the market. Similarly, investors tend to give Kimberly-Clark a slightly premium valuation given its stable and reliable dividend and recession-resistant business model. But now, the company is trading at its lowest valuation in years. Like most retailers, Target typically trades at a discount to the S&P 500. But its valuation is so cheap, the stock's P/E ratio is within striking distance of hitting single digits. Three Dividend Kings that have fallen far enough Pepsi, Kimberly-Clark, and Target stand out as excellent values, especially for patient investors looking to boost their passive income streams. Not only do these companies have exceptional track records of growing their payouts, but they can also afford their dividends thanks to strong earnings. What's more, all three companies have high yields -- Pepsi at 4.3%, Kimberly-Clark at 3.9%, and Target at 4.5%. Short-term-minded investors are making a mistake by dumping these stocks just because their results haven't been great lately. Long-term investors who can filter out the noise are getting the chance to buy these names at compelling valuations. Should you invest $1,000 in PepsiCo right now? Before you buy stock in PepsiCo, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and PepsiCo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $697,627!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $939,655!* Now, it's worth noting Stock Advisor 's total average return is1,045% — a market-crushing outperformance compared to178%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Daniel Foelber has positions in PepsiCo. The Motley Fool has positions in and recommends Target and Walmart. The Motley Fool has a disclosure policy.
Globe and Mail
an hour ago
- Globe and Mail
Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth
Explore the exciting world of Kiniksa Pharmaceuticals (NASDAQ: KNSA) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of May 28, 2025. The video was published on Jul. 2, 2025. Should you invest $1,000 in Kiniksa Pharmaceuticals International right now? Before you buy stock in Kiniksa Pharmaceuticals International, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kiniksa Pharmaceuticals International wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $697,627!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $939,655!* Now, it's worth noting Stock Advisor 's total average return is1,045% — a market-crushing outperformance compared to178%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Anand Chokkavelu, CFA has no position in any of the stocks mentioned. Karl Thiel has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Kiniksa Pharmaceuticals International, Plc. The Motley Fool has a disclosure policy.
CTV News
an hour ago
- CTV News
Health experts push province to bolster flu vaccine campaign amid low uptake
The Alberta government is facing calls to strengthen its flu shot campaign next season after seeing the lowest record of vaccinations in the province since 2009-2010, with 21 per-cent of Albertans opting for the shot. Pharmacist Noreen Walji with Co-op Pharmacy in Edmonton said the pharmacy has seen a steady decline in flu vaccinations over the past three years. Walji attributes the drop in numbers to vaccine apathy following COVID-19 and misinformation on social media and other online platforms. 'There is a lot of vaccine hesitancy around the flu shot this year and in prior years,' she told CTV News Edmonton in an interview on Wednesday. 'We're seeing lower than normal upticks for the flu vaccine.' Co-op Pharmacy in Edmonton (Evan Kenny/CTV News Edmonton) Co-op Pharmacy in Edmonton on July 2, 2025. (Evan Kenny/CTV News Edmonton) She recommends people talk to their healthcare providers or to a pharmacist if they have anxieties around the vaccine, citing the vaccine is safe and that 20 per-cent of all flu cases ended in hospitalizations in 2023-2024. 'There are so many studies showing the efficacy of the vaccine and (its) safety, and the fact that it reduces the complications due to influenza (and) potentially pneumonia-causing hospitalizations,' Walji said, adding that the vaccine has been around for more than a decade. There were 235 influenza-related deaths in Alberta for the 2024-2025 season. The province cautioned against comparing that number to previous years since it changed how it investigates and confirms deaths from the virus, including starting to count deaths outside hospitals. Walji said the government is doing a 'decent job promoting the flu vaccine,' but that its messaging could be more widespread. 'Promoting the flu shot is going to be very critical,' she said. 'We saw the lowest uptake of flu vaccine that we had seen in decades.' 'It is a drastic decline that we do need to see additional support through Alberta Health Services to showcase and highlight the importance of receiving the flu vaccine, especially with a lot of that vaccine apathy happening.' A hospital in Alberta (File) A supplied photo of a hospital in Alberta. (File) 'It's important to note that declining influenza vaccination rates are being observed across the country and are not unique to Alberta,' the province said in a statement to CTV News Edmonton. 'Many factors influence influenza trends, including viral characteristics, behavioural patterns, and global trends.' Officials added that reduced numbers of people getting the flu shot, and the increased circulation of influenza strains H1N1 and H3N2, likely caused the 'increased severity' of the flu this past season. Walji hopes the province can be more active on different platforms and provide patients with more immediate resources and tools from fact checking to healthcare referrals. Minor side effects from the flu vaccine can include slight fever, runny nose, itchy eyes, and sore muscles. Walji added that it is easy to get the flu shot by visiting a pharmacy. 'It's not something that takes up too much time during the day and can save yourself or a loved one from serious complications in the future.' The province is currently in the planning stages for the 2025-2026 respiratory virus season. With files from CTV News Edmonton's Evan Kenny and Alesia Fieldberg
